An Extension To A Phase II Study to Determine The Efficacy and Safety of STI1571 in Patients With Chronic Myeloid Leukemia And Are Refractory To Or Intolerant of Interferon-Alpha
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 25 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Mar 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2013 to 1 Mar 2014.
- 23 Apr 2013 Planned End Date changed from 1 Jul 2015 to 1 Apr 2013 as reported by ClinicalTrials.gov.